<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2017-23-5-447-456</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-687</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОР</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEW</subject></subj-group></article-categories><title-group><article-title>МОРФОФУНКЦИОНАЛЬНЫЕ ИЗМЕНЕНИЯ ЭНДОТЕЛИЯ В ПАТОГЕНЕЗЕ ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНИ</article-title><trans-title-group xml:lang="en"><trans-title>MORPHOFUNCTIONAL ALTERATIONS IN ENDOTHELIUM IN THE PATHOGENESIS OF ESSENTIAL HYPERTENSION</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сысоев</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Sysoev</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сысоев Кирилл Александрович — лаборатория середечнососудистой и лимфатической систем Института физиологии им. И. П. Павлова РАН; научный сотрудник НИО ишемической болезни сердца ФГБУ «НМИЦ им. В. А. Алмазова» Минздрава России.</p><p>наб. Макарова, д. 6, Санкт-Петербург, 199034.</p></bio><bio xml:lang="en"><p>Kirill A. Sysoev, Pavlov Institute of Physiology of the Russian Academy of Sciences; Researcher, Research Department of Coronary Heart Disease, Almazov National Medical Research Centre.</p><p>6 Makarov embankment, St Petersburg, 199034.</p></bio><email xlink:type="simple">sysoev@infran.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное учреждение  «Национальный медицинский исследовательский  центр имени В. А. Алмазова» Министерства здравоохранения  Российской Федерации;  Федеральное государственное бюджетное учреждение  науки «Институт физиологии имени И. П. Павлова»  Российской академии наук.</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Almazov National Medical Research Centre; Pavlov Institute of Physiology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>02</day><month>11</month><year>2017</year></pub-date><volume>23</volume><issue>5</issue><fpage>447</fpage><lpage>456</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сысоев К.А., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Сысоев К.А.</copyright-holder><copyright-holder xml:lang="en">Sysoev K.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/687">https://htn.almazovcentre.ru/jour/article/view/687</self-uri><abstract><p>Эндотелий представляет собой многоуровневую клеточную структуру, пронизывающую все органы и системы организма. Гипертоническая болезнь (ГБ) является заболеванием, в основе патогенеза которого лежит нарушение регуляции тонуса магистральных артерий. Патогенетические основы ГБ, несмотря на интенсивные усилия, остаются неясными. Бесспорна неблагоприятная роль эмоционального стресса, гиподинамии, ожирения и нарушений водно-солевого обмена. Вместе с тем точные механизмы и предикторы развития артериальной гипертензии (АГ) в настоящее время не определены. Это препятствует профилактике и выявлению эссенциальной гипертензии на ранней стадии. Изучение функции эндотелия как мишени и предрасполагающего фона развития ГБ является задачей, имеющей как исследовательское, так и прикладное, клиническое значение. Действительно, если удастся выявить патогномоничные для развития АГ изменения эндотелиальной функции, — это позволит прояснить патогенетические основы заболевания и разработать адекватные медикаментозные схемы терапии. В обзоре рассмотрены накопленные на настоящее время данные по участию эндотелиальных клеток (ЭК) в развитии ГБ. Показан вклад изменений липидного обмена в физиологическое состояние эндотелиальной выстилки. Освещена роль нарушений эндотелиальной функции в увеличении продукции активных форм кислорода и дефектов метаболизма оксида азота. Продемонстрирована изученная авторскими коллективами активность следующих ферментных систем: НАДФН (никотинамидадениндинуклеотидфосфат)-оксидазы, циклооксигеназы, кcантиноксидоредуктазы и эндотелиальной NO-синтазы. Взаимодействие эндотелия и внеклеточного матрикса, а также эндотелия и гладкомышечных клеток также приведено согласно литературным данным. Освещена роль грелина, продуцируемого эндотелием в регуляции сосудистого тонуса. Показаны методические подходы к изучению ЭК in vitro в условиях гипоксии. Основным итогом проведенного анализа литературных данных является необходимость исследования функции эндотелия в условиях гипоксии in vitro, а также влияние тканевой и гемической гипоксии in vivo, что позволит установить вклад функциональных нарушений эндотелия в развитие ГБ.</p></abstract><trans-abstract xml:lang="en"><p>Endothelium is a multilevel cellular structure that permeates all organs and systems of the body. A disorder of the regulation of the arterial tone underlies essential hypertension. However, its pathogenesis basis, despite intense efforts, remains unclear. The unfavorable role of emotional stress, hypodynamia, obesity and disorder of water-salt metabolism is obvious. However, the exact mechanisms and predictors of the development of arterial hypertension (HTN) are not currently defined. This opposes the prevention and detection of essential hypertension at an early stage. The investigation of endothelial function as a target and a predisposing factor for HTN development is promising and implies both scientific and applied clinical significance. Indeed, understanding of pathognomonic endothelial alterations for HTN development will clarify its pathogenesis and will help the development of the adequate treatment protocols. The paper reviews current data on the involvement of endothelial cells (EC) in the development of HTN. The role of lipid disorders in the physiological state of the endothelium is shown. The role of endothelial dysfunction in increasing production of active oxygen species and disorders in the nitric oxide metabolism is highlighted. The activity of the following enzyme is reviewed: NADPH (nicotinamide adenine dinucleotide phosphate) oxidase, cyclooxygenase, xantinoxydoreductase and endothelial NO synthase. The interaction of the endothelium and the extracellular matrix, as well as endothelium and smooth muscle cells, is also given according to the literature data. The role of ghrelin, produced by endothelium, in the regulation of vascular tone is highlighted. Methods of the EC assessment in vitro under hypoxia are presented. Based on the literature review, it is clear that the assessment of the endothelium under hypoxia is highly important, as well as the investigation of the influence of tissue and hemic hypoxia in vivo. These studies will help to establish the contribution of functional endothelial disturbances to the development of HTN.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>артериальная гипертензия</kwd><kwd>гипертоническая болезнь</kwd><kwd>эндотелий</kwd><kwd>эндотелиальные клетки</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arterial hypertension</kwd><kwd>essential hypertension</kwd><kwd>endothelium</kwd><kwd>endothelial cells</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Lubrano V, Balzan S. Roles of LOX-1 in microvascular dysfunction. Microvasc Res. 2016;105:132–40. doi:10.1016/j. mvr.2016.02.006</mixed-citation><mixed-citation xml:lang="en">Lubrano V, Balzan S. Roles of LOX-1 in microvascular dysfunction. Microvasc Res. 2016;105:132–40. doi:10.1016/j. mvr.2016.02.006</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Chen M, Masaki T, SawamuraT. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther. 2002;95(1):89–100.</mixed-citation><mixed-citation xml:lang="en">Chen M, Masaki T, SawamuraT. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther. 2002;95(1):89–100.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kenney WL, Cannon JG, Alexander LM. Cutaneous microvascular dysfunction correlates with serum LDL and sLOX-1 receptor concentrations. Microvasc Res. 2013;85:112–17. doi:10.1016/j.mvr.2012.10.010</mixed-citation><mixed-citation xml:lang="en">Kenney WL, Cannon JG, Alexander LM. Cutaneous microvascular dysfunction correlates with serum LDL and sLOX-1 receptor concentrations. Microvasc Res. 2013;85:112–17. doi:10.1016/j.mvr.2012.10.010</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Holowatz LA, Santhanam L, Webb A, Berkowitz DE, Kenney WL. Oral atorvastatin therapy restores cutaneous microvascular function by decreasing arginase activity in hypercholesterolaemic humans. J Physiol. 2011;589(Pt 8):2093–103. doi:10.1113/jphysiol.2010.203935</mixed-citation><mixed-citation xml:lang="en">Holowatz LA, Santhanam L, Webb A, Berkowitz DE, Kenney WL. Oral atorvastatin therapy restores cutaneous microvascular function by decreasing arginase activity in hypercholesterolaemic humans. J Physiol. 2011;589(Pt 8):2093–103. doi:10.1113/jphysiol.2010.203935</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">García-Redondo AB, Aguado A, Briones AM, Salaices M. NADPH oxidases and vascular remodeling in cardiovascular diseases. Pharmacol Res. 2016;114:110–20. doi:10.1016/j. phrs.2016.10.015</mixed-citation><mixed-citation xml:lang="en">García-Redondo AB, Aguado A, Briones AM, Salaices M. NADPH oxidases and vascular remodeling in cardiovascular diseases. Pharmacol Res. 2016;114:110–20. doi:10.1016/j. phrs.2016.10.015</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Forte M, Nocella C, De Falco E, Palmerio S, Schirone L, Valenti V et al. The pathophysiological role of NOX2 in hypertension and organ damage. High Blood Press Cardiovasc Prev. 2016;23 (4):355–64. doi:10.1007/s40292–016–0175-y</mixed-citation><mixed-citation xml:lang="en">Forte M, Nocella C, De Falco E, Palmerio S, Schirone L, Valenti V et al. The pathophysiological role of NOX2 in hypertension and organ damage. High Blood Press Cardiovasc Prev. 2016;23 (4):355–64. doi:10.1007/s40292–016–0175-y</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Sahoo S, Meijles DN, Pagano PJ. NADPH oxidases: key modulators in aging and age-related cardiovascular diseases? Clin Sci (Lond). 2016;130(5):317–35. doi:10.1042/CS20150087</mixed-citation><mixed-citation xml:lang="en">Sahoo S, Meijles DN, Pagano PJ. NADPH oxidases: key modulators in aging and age-related cardiovascular diseases? Clin Sci (Lond). 2016;130(5):317–35. doi:10.1042/CS20150087</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Nurkiewicz TR, Wu G, Li P, Boegehold MA. Decreased arteriolar tetrahydrobiopterin is linked to superoxide generation from nitric oxide synthase in mice fed high salt. Microcirculation. 2010;17(2):147–57. doi:10.1111/j.1549–8719.2009.00014.x</mixed-citation><mixed-citation xml:lang="en">Nurkiewicz TR, Wu G, Li P, Boegehold MA. Decreased arteriolar tetrahydrobiopterin is linked to superoxide generation from nitric oxide synthase in mice fed high salt. Microcirculation. 2010;17(2):147–57. doi:10.1111/j.1549–8719.2009.00014.x</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Channon KM. Tetrahydrobiopterin: Regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc Med. 2004;14(8):323–27. doi:10.1016/j.tcm.2004.10.003</mixed-citation><mixed-citation xml:lang="en">Channon KM. Tetrahydrobiopterin: Regulator of endothelial nitric oxide synthase in vascular disease. Trends Cardiovasc Med. 2004;14(8):323–27. doi:10.1016/j.tcm.2004.10.003</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014;2014:406960. doi:10.1155/ 2014/406960</mixed-citation><mixed-citation xml:lang="en">Dinh QN, Drummond GR, Sobey CG, Chrissobolis S. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014;2014:406960. doi:10.1155/ 2014/406960</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56(3):387–437. doi:10.1124/pr.56.3.3</mixed-citation><mixed-citation xml:lang="en">Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56(3):387–437. doi:10.1124/pr.56.3.3</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Feletou M, Huang Y, Vanhoutte PM. Endotheliummediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol. 2011;164(3):894–912. doi:10.1111/j.1476–5381. 2011.01276.x</mixed-citation><mixed-citation xml:lang="en">Feletou M, Huang Y, Vanhoutte PM. Endotheliummediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol. 2011;164(3):894–912. doi:10.1111/j.1476–5381. 2011.01276.x</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Virdis A, Taddei S. Endothelial dysfunction in resistance arteries of hypertensive humans: old and new conspirators. J Cardiovasc Pharmacol. 2016;67(6):451–57. doi:10.1097/FJC. 0000000000000362</mixed-citation><mixed-citation xml:lang="en">Virdis A, Taddei S. Endothelial dysfunction in resistance arteries of hypertensive humans: old and new conspirators. J Cardiovasc Pharmacol. 2016;67(6):451–57. doi:10.1097/FJC. 0000000000000362</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kelley EE. A new paradigm for XOR-catalyzed reactive species generation in the endothelium. Pharmacol Rep. 2015;67 (4):669–74. doi:10.1016/j.pharep.2015.05.004</mixed-citation><mixed-citation xml:lang="en">Kelley EE. A new paradigm for XOR-catalyzed reactive species generation in the endothelium. Pharmacol Rep. 2015;67 (4):669–74. doi:10.1016/j.pharep.2015.05.004</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Enroth C, Eger BT, Okamoto K, Nishino T, Nishino T, Pai EF. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: Structure-based mechanism of conversion. Proc Natl Acad Sci USA. 2000;97(20):10723–8.</mixed-citation><mixed-citation xml:lang="en">Enroth C, Eger BT, Okamoto K, Nishino T, Nishino T, Pai EF. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: Structure-based mechanism of conversion. Proc Natl Acad Sci USA. 2000;97(20):10723–8.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Maia LB, Moura JJ. Nitrite reduction by xanthine oxidase family enzymes: a new class of nitrite reductases. J Biol Inorg Chem. 2011;16(3):443–460. doi:10.1007/s00775–010–0741-z</mixed-citation><mixed-citation xml:lang="en">Maia LB, Moura JJ. Nitrite reduction by xanthine oxidase family enzymes: a new class of nitrite reductases. J Biol Inorg Chem. 2011;16(3):443–460. doi:10.1007/s00775–010–0741-z</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660. doi:10.1038/45230</mixed-citation><mixed-citation xml:lang="en">Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone releasing acylated peptide from stomach. Nature. 1999;402(6762):656–660. doi:10.1038/45230</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kleinz MJ, Maguire JJ, Skepper JN, Davenport AP. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovasc Res. 2006;69(1):227–35. doi:10.1016/j. cardiores.2005.09.001</mixed-citation><mixed-citation xml:lang="en">Kleinz MJ, Maguire JJ, Skepper JN, Davenport AP. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovasc Res. 2006;69(1):227–35. doi:10.1016/j. cardiores.2005.09.001</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Iglesias MJ, Pineiro R, Blanco M, Gallego R, Diéguez C, Gualillo O et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res. 2004;62(93):481–488. doi:10.1016/j.cardiores.2004.01.024</mixed-citation><mixed-citation xml:lang="en">Iglesias MJ, Pineiro R, Blanco M, Gallego R, Diéguez C, Gualillo O et al. Growth hormone releasing peptide (ghrelin) is synthesized and secreted by cardiomyocytes. Cardiovasc Res. 2004;62(93):481–488. doi:10.1016/j.cardiores.2004.01.024</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation. 2005;112(19):2986–92. doi:10.1161/circulationaha.105.553883</mixed-citation><mixed-citation xml:lang="en">Tesauro M, Schinzari F, Iantorno M, Rizza S, Melina D, Lauro D et al. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation. 2005;112(19):2986–92. doi:10.1161/circulationaha.105.553883</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kawczynska-Drozdz A, Olszanecki R, Jawien J, Brzozowski T, Pawlik WW, Korbut R et al. Ghrelin inhibits vascular superoxide production in spontaneously hypertensive rats. Am J Hypertens. 2006;19(7):764–7. doi:10.1016/j.amjhyper.2006.01.022</mixed-citation><mixed-citation xml:lang="en">Kawczynska-Drozdz A, Olszanecki R, Jawien J, Brzozowski T, Pawlik WW, Korbut R et al. Ghrelin inhibits vascular superoxide production in spontaneously hypertensive rats. Am J Hypertens. 2006;19(7):764–7. doi:10.1016/j.amjhyper.2006.01.022</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Tesauro M, Schinzari F, Rovella V, Di Daniele N, Lauro D, Mores N et al. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension. 2009;54(5):995–1000. doi:10.1161/HYPERTENSIONAHA. 109.137729</mixed-citation><mixed-citation xml:lang="en">Tesauro M, Schinzari F, Rovella V, Di Daniele N, Lauro D, Mores N et al. Ghrelin restores the endothelin 1/nitric oxide balance in patients with obesity-related metabolic syndrome. Hypertension. 2009;54(5):995–1000. doi:10.1161/HYPERTENSIONAHA. 109.137729</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">de Wit C, Griffith TM. Connexins and gap junctions in the EDHF phenomenon and conducted vasomotor responses. Pflugers Arch. 2010;459(6):897–914. doi:10.1007/s00424–010–0830–4</mixed-citation><mixed-citation xml:lang="en">de Wit C, Griffith TM. Connexins and gap junctions in the EDHF phenomenon and conducted vasomotor responses. Pflugers Arch. 2010;459(6):897–914. doi:10.1007/s00424–010–0830–4</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Maguire JJ, Skepper JN, Skepper JN, Davenport AP. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovasc Res. 2006;69(1):227–235.</mixed-citation><mixed-citation xml:lang="en">Maguire JJ, Skepper JN, Skepper JN, Davenport AP. Functional and immunocytochemical evidence for a role of ghrelin and des-octanoyl ghrelin in the regulation of vascular tone in man. Cardiovasc Res. 2006;69(1):227–235.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Félétou M, Vanhoutte PM. Endothelium-dependent hyperpolarizations: past beliefs and present facts. Ann Med. 2007;39 (7):495–516.</mixed-citation><mixed-citation xml:lang="en">Félétou M, Vanhoutte PM. Endothelium-dependent hyperpolarizations: past beliefs and present facts. Ann Med. 2007;39 (7):495–516.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Chou TC, Yen MH, Li CY, Ding YA. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension. 1998;31(2):643–8.</mixed-citation><mixed-citation xml:lang="en">Chou TC, Yen MH, Li CY, Ding YA. Alterations of nitric oxide synthase expression with aging and hypertension in rats. Hypertension. 1998;31(2):643–8.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kondrashov A, Vrankova S, Dovinová I, Sevčík R, Parohová J, Barta A et al. The effects of new Alibernet red wine extract on nitric oxide and reactive oxygen species production in spontaneously hypertensive rats. Oxid Med Cell Longev. 2012; 2012:806285. doi:10.1155/2012/806285</mixed-citation><mixed-citation xml:lang="en">Kondrashov A, Vrankova S, Dovinová I, Sevčík R, Parohová J, Barta A et al. The effects of new Alibernet red wine extract on nitric oxide and reactive oxygen species production in spontaneously hypertensive rats. Oxid Med Cell Longev. 2012; 2012:806285. doi:10.1155/2012/806285</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Nava E, Noll G, Luscher TF. Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation. 1995;91(9):2310–3.</mixed-citation><mixed-citation xml:lang="en">Nava E, Noll G, Luscher TF. Increased activity of constitutive nitric oxide synthase in cardiac endothelium in spontaneous hypertension. Circulation. 1995;91(9):2310–3.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Al-Gburi S, Deussen A, Zatschler B, Weber S, Künzel S, El-Armouche A et al. Sex-difference in expression and function of beta-adrenoceptors in macrovessels: role of the endothelium. Basic Res Cardiol. 2017;112(3):29. doi:10.1007/s00395–017–0617–2</mixed-citation><mixed-citation xml:lang="en">Al-Gburi S, Deussen A, Zatschler B, Weber S, Künzel S, El-Armouche A et al. Sex-difference in expression and function of beta-adrenoceptors in macrovessels: role of the endothelium. Basic Res Cardiol. 2017;112(3):29. doi:10.1007/s00395–017–0617–2</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Caniffi C, Cerniello FM, Gobetto MN, Sueiro ML, Costa MA, Arranz C. Vascular tone regulation induced by C-type natriuretic peptide: differences in endothelium-dependent and independent mechanisms involved in normotensive and spontaneously hypertensive rats. PLoS One. 2016;11(12):e0167817. doi:10.1371/journal.pone.0167817</mixed-citation><mixed-citation xml:lang="en">Caniffi C, Cerniello FM, Gobetto MN, Sueiro ML, Costa MA, Arranz C. Vascular tone regulation induced by C-type natriuretic peptide: differences in endothelium-dependent and independent mechanisms involved in normotensive and spontaneously hypertensive rats. PLoS One. 2016;11(12):e0167817. doi:10.1371/journal.pone.0167817</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Nakao K, Kuwahara K, Nishikimi T, Nakagawa Y, Kinoshita H, Minami T et al. Endothelium-derived C-type natriuretic peptide contributes to blood pressure regulation by maintaining endothelial integrity. Hypertension. 2017;69(2):286– 296. doi:10.1161/HYPERTENSIONAHA.116.08219</mixed-citation><mixed-citation xml:lang="en">Nakao K, Kuwahara K, Nishikimi T, Nakagawa Y, Kinoshita H, Minami T et al. Endothelium-derived C-type natriuretic peptide contributes to blood pressure regulation by maintaining endothelial integrity. Hypertension. 2017;69(2):286– 296. doi:10.1161/HYPERTENSIONAHA.116.08219</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications Can J Cardiol. 2016;32(5):659–68. doi:10. 1016/j.cjca.2016.02.070</mixed-citation><mixed-citation xml:lang="en">Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications Can J Cardiol. 2016;32(5):659–68. doi:10. 1016/j.cjca.2016.02.070</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Gutterman DD, Chabowski DS, Kadlec AO, Durand MJ, Freed JK, Ait-Aissa K et al. The human microcirculation. Regulation of flow and beyond. Circ Res. 2016;118(1):157–72. doi:10.1161/CIRCRESAHA.115.305364</mixed-citation><mixed-citation xml:lang="en">Gutterman DD, Chabowski DS, Kadlec AO, Durand MJ, Freed JK, Ait-Aissa K et al. The human microcirculation. Regulation of flow and beyond. Circ Res. 2016;118(1):157–72. doi:10.1161/CIRCRESAHA.115.305364</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Fruchart JC. Peroxisome proliferatoractivated receptoralpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009;205(1):1–8. doi:10.1016/j.atherosclerosis.2009.03.008</mixed-citation><mixed-citation xml:lang="en">Fruchart JC. Peroxisome proliferatoractivated receptoralpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis. 2009;205(1):1–8. doi:10.1016/j.atherosclerosis.2009.03.008</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Glineur C, Gross B, Neve B, Rommens C, Chew GT, Martin-Nizard F et al. Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor α-dependent and independent mechanisms in human endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33(3):621–8. doi:10.1161/ ATVBAHA.112.300665</mixed-citation><mixed-citation xml:lang="en">Glineur C, Gross B, Neve B, Rommens C, Chew GT, Martin-Nizard F et al. Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor α-dependent and independent mechanisms in human endothelial cells. Arterioscler Thromb Vasc Biol. 2013;33(3):621–8. doi:10.1161/ ATVBAHA.112.300665</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Jíchová Š, Doleželová Š, Kopkan L, KompanowskaJezierska E, Sadowski J, Červenka L. Fenofibrate attenuates malignant hypertension by suppression of the renin-angiotensin system: a study in Cyp1a1-Ren-2 transgenic rats. Am J Med Sci. 2016;352(6):618–630. doi:10.1016/j.amjms.2016.09.008</mixed-citation><mixed-citation xml:lang="en">Jíchová Š, Doleželová Š, Kopkan L, KompanowskaJezierska E, Sadowski J, Červenka L. Fenofibrate attenuates malignant hypertension by suppression of the renin-angiotensin system: a study in Cyp1a1-Ren-2 transgenic rats. Am J Med Sci. 2016;352(6):618–630. doi:10.1016/j.amjms.2016.09.008</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Kvandová M, Majzúnová M, Dovinová I. The role of PPARgamma in cardiovascular diseases. Physiol Res. 2016;65 (S3): S343-S363.</mixed-citation><mixed-citation xml:lang="en">Kvandová M, Majzúnová M, Dovinová I. The role of PPARgamma in cardiovascular diseases. Physiol Res. 2016;65 (S3): S343-S363.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Nauta TD, van den Broek M, Gibbs S, van der Pouw-Kraan TC, Oudejans CB, van Hinsbergh VW et al. Identification of HIF-2αregulated genes that play a role in human microvascular endothelial sprouting during prolonged hypoxia in vitro. Angiogenesis. 2017;20 (1):39–54. doi:10.1007/s10456–016–9527–4</mixed-citation><mixed-citation xml:lang="en">Nauta TD, van den Broek M, Gibbs S, van der Pouw-Kraan TC, Oudejans CB, van Hinsbergh VW et al. Identification of HIF-2αregulated genes that play a role in human microvascular endothelial sprouting during prolonged hypoxia in vitro. Angiogenesis. 2017;20 (1):39–54. doi:10.1007/s10456–016–9527–4</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Befani C, Liakos P. Hypoxia upregulates integrin gene expression in microvascular endothelial cells and promotes their migration and capillary-like tube formation. Cell Biol Int. 2017;41 (7):769–778.</mixed-citation><mixed-citation xml:lang="en">Befani C, Liakos P. Hypoxia upregulates integrin gene expression in microvascular endothelial cells and promotes their migration and capillary-like tube formation. Cell Biol Int. 2017;41 (7):769–778.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Daiber A, Di Lisa F, Oelze M, Kröller-Schön S, Steven S, Schulz E et al. Crosstalk of mitochondria with NADPH oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function. Br J Pharmacol. 2017;174(12):1670–1689. doi:10.1111/bph.13403</mixed-citation><mixed-citation xml:lang="en">Daiber A, Di Lisa F, Oelze M, Kröller-Schön S, Steven S, Schulz E et al. Crosstalk of mitochondria with NADPH oxidase via reactive oxygen and nitrogen species signalling and its role for vascular function. Br J Pharmacol. 2017;174(12):1670–1689. doi:10.1111/bph.13403</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Koziel A, Jarmuszkiewicz W. Hypoxia and aerobic metabolism adaptations of human endothelial cells. Pflugers Arch. 2017;469(5–6):815–27. doi:10.1007/s00424–017–1935–9</mixed-citation><mixed-citation xml:lang="en">Koziel A, Jarmuszkiewicz W. Hypoxia and aerobic metabolism adaptations of human endothelial cells. Pflugers Arch. 2017;469(5–6):815–27. doi:10.1007/s00424–017–1935–9</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Hernansanz-Agustín P, Ramos E, Navarro E, Parada E, Sánchez-López N, Peláez-Aguado L et al. Mitochondrial complex I deactivation is related to superoxide production in acute hypoxia. Redox Biol. 2017;12:1040–1051. doi:10.1016/j. redox.2017.04.025</mixed-citation><mixed-citation xml:lang="en">Hernansanz-Agustín P, Ramos E, Navarro E, Parada E, Sánchez-López N, Peláez-Aguado L et al. Mitochondrial complex I deactivation is related to superoxide production in acute hypoxia. Redox Biol. 2017;12:1040–1051. doi:10.1016/j. redox.2017.04.025</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Biancardi VC, Bomfim GF, Reis WL, Al-Gassimi S, Nunes KP. The interplay between Angiotensin II, TLR4 and hypertension. Pharmacol Res. 2017;120:88–96. doi:10.1016/j.phrs.2017.03.017</mixed-citation><mixed-citation xml:lang="en">Biancardi VC, Bomfim GF, Reis WL, Al-Gassimi S, Nunes KP. The interplay between Angiotensin II, TLR4 and hypertension. Pharmacol Res. 2017;120:88–96. doi:10.1016/j.phrs.2017.03.017</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">De Batista PR, Palacios R, Martín A, Hernanz R, Médici CT, Silva MA et al. Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. PloS One. 2014;9(8): e104020. doi:10.1371/journal.pone.0104020</mixed-citation><mixed-citation xml:lang="en">De Batista PR, Palacios R, Martín A, Hernanz R, Médici CT, Silva MA et al. Toll-like receptor 4 upregulation by angiotensin II contributes to hypertension and vascular dysfunction through reactive oxygen species production. PloS One. 2014;9(8): e104020. doi:10.1371/journal.pone.0104020</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Bomfim GF, Dos Santos RA, Oliveira MA, Giachini FR, Akamine EH, Tostes RC et al. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci (Lond). 2012;122(12):535–543. doi:10.1111/bph.13117</mixed-citation><mixed-citation xml:lang="en">Bomfim GF, Dos Santos RA, Oliveira MA, Giachini FR, Akamine EH, Tostes RC et al. Toll-like receptor 4 contributes to blood pressure regulation and vascular contraction in spontaneously hypertensive rats. Clin Sci (Lond). 2012;122(12):535–543. doi:10.1111/bph.13117</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Hernanz R, Martinez-Revelles S, Palacios R, Martin A, Cachofeiro V, Aguado A et al. Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin IIinduced hypertension. Br J Pharmacol. 2015;172(12):3159–3176. doi:10.1111/bph.13117</mixed-citation><mixed-citation xml:lang="en">Hernanz R, Martinez-Revelles S, Palacios R, Martin A, Cachofeiro V, Aguado A et al. Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin IIinduced hypertension. Br J Pharmacol. 2015;172(12):3159–3176. doi:10.1111/bph.13117</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Bomfim GF, Echem C, Martins CB, Costa TJ, Sartoretto SM, Dos Santos RA et al. Toll-like receptor 4 inhibition reduces vas cular inflammation in spontaneously hypertensive rats. Life Sci. 2015;122:1–7. doi:10.1016/j.lfs.2014.12.001</mixed-citation><mixed-citation xml:lang="en">Bomfim GF, Echem C, Martins CB, Costa TJ, Sartoretto SM, Dos Santos RA et al. Toll-like receptor 4 inhibition reduces vas cular inflammation in spontaneously hypertensive rats. Life Sci. 2015;122:1–7. doi:10.1016/j.lfs.2014.12.001</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">McCarthy CG, Wenceslau CF, Goulopoulou S, Ogbi S, Baban B, Sullivan JC et al. Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc Res. 2015;107(1):119– 130. doi:10.1093/cvr/cvv137</mixed-citation><mixed-citation xml:lang="en">McCarthy CG, Wenceslau CF, Goulopoulou S, Ogbi S, Baban B, Sullivan JC et al. Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc Res. 2015;107(1):119– 130. doi:10.1093/cvr/cvv137</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Mian MO, Barhoumi T, Briet M, Paradis P, Schiffrin EL. Deficiency of T-regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. J Hypertens. 2016;34(1):97–108. doi:10.1097/HJH.0000000000000761</mixed-citation><mixed-citation xml:lang="en">Mian MO, Barhoumi T, Briet M, Paradis P, Schiffrin EL. Deficiency of T-regulatory cells exaggerates angiotensin II-induced microvascular injury by enhancing immune responses. J Hypertens. 2016;34(1):97–108. doi:10.1097/HJH.0000000000000761</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
